Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Piha-Paul is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Baylor College of MedicineResidency, Internal Medicine, 2002 - 2006
Louisiana State University School of Medicine in New OrleansClass of 2002
Certifications & Licensure
FL State Medical License 2024 - Present
GA State Medical License 2024 - 2028
AZ State Medical License 2024 - 2027
LA State Medical License 2024 - 2027
MS State Medical License 2024 - 2027
TN State Medical License 2024 - 2027
TX State Medical License 2008 - 2027
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013, 2015
Clinical Trials
- Bevacizumab and Temsirolimus in Patients With Advanced Malignancy Start of enrollment: 2008 Jan 25
- FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies Start of enrollment: 2009 Apr 09
- FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2010 Jun 01
Publications & Presentations
PubMed
- Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.Mohamed H Derbala, Bettzy Stephen, Woochan Hwang, Chan-Young Ock, Soohyun Hwang
Journal for Immunotherapy of Cancer. 2026-06-24 - Biomarker study of pembrolizumab in patients with advanced rare cancers.Aung Naing, Xiqi Li, Qi Wang, Xiangjun Jun Tian, Sharjeel Sabir
Cell Reports. Medicine. 2026-06-16 - 1 citationsFirst-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung C...Solange Peters, Sarina A Piha-Paul, Kartik Sehgal, Emiliano Calvo, Bruno Bockorny
Journal of Clinical Oncology. 2026-06-10
Lectures
- A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
- Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplifi...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/re...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
MD Anderson Research Highlights for July 16, 2025July 16th, 2025- MD Anderson Unveils Breakthrough Research Findings – February 10, 2025February 10th, 2025
Signature Trial Program Aims for Rapid Delivery of Novel TherapiesAugust 4th, 2016
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
